Dr. Harrison Nguyen | Double Board-Certified Dermatologist and Mohs Surgeon
Nationally recognized. Patient-focused. Precision-driven skin care
About Dr. Harrison Nguyen
Dr. Harrison P. Nguyen, MD, MBA, MPH, DTM&H, FAAD, is an award-winning, Ivy-league educated and trained double board-certified dermatologist and fellowship-trained Mohs micrographic surgeon, proudly serving the Missouri City and Houston area. As the Managing Director of Harrison Dermatology & Research Group, he brings a unique blend of medical expertise, academic leadership, and innovative skin care solutions to patients seeking exceptional dermatologic care.
An NIH-funded clinical researcher and respected educator, Dr. Nguyen also serves as a Clinical Assistant Professor of Dermatology and Health Economics at the University of Houston College of Medicine. His dedication to advancing dermatology through both patient care and policy leadership distinguishes him as a trusted name in the field.
Dr. Nguyen graduated with honors from Rice University, where he also played as an All-Conference Linebacker for the Rice Owls Football Team. He earned his medical degree from Baylor College of Medicine, an MBA from Yale School of Management, an MPH from Yale School of Public Health, and a DTM&H from the National School of Tropical Medicine. He then completed Dermatology Residency at Emory University School of Medicine, where he served as Chief Resident, followed by a rigorous Advanced Fellowship in Mohs Micrographic Surgery and Facial Plastic and Reconstructive Surgery at the University of Pennsylvania. He is one of the first physicians to achieve double board-certification in both dermatology and Mohs micrographic surgery, and his training background is uniquely cross-pollinated with integrated training in Mohs micrographic surgery, facial plastic surgery, oculoplastic surgery, dermatologic surgery, and general plastic surgery.
In addition to leading patient care at Harrison Dermatology, Dr. Nguyen serves on the Editorial Boards of the Journal of Clinical and Aesthetic Dermatology and the Journal of Cutaneous Medicine, and has authored over 100 peer-reviewed scientific publications. He also leads the Health Policy Research Group for the American Academy of Dermatology and has been a Visiting Professor at prestigious institutions including Oregon Health & Science University and Baylor College of Medicine.
When he’s not in clinic or teaching in the classroom, Dr. Nguyen enjoys fitness training, boxing, and Latin dance—especially salsa and bachata. A lifelong athlete, he remains an enthusiastic football fan.
Specialties & Services
- Mohs Micrographic Surgery
- Skin Cancer Diagnosis and Treatment
- Acne, Eczema, Psoriasis Treatment
- Hidradenitis Suppurativa Treatment
- Cyst/Lipoma Surgery
- Skin Resurfacing and Scar Revision
- Botox and Dermal Fillers
Patient Testimonials
Clinical Trial Leadership
- Principal Investigator: Performance of Advance AD-Tx to Align Appropriate Treatment for Patients Utilizing Systemic Treatment for Atopic Dermatitis (ALIGN-AD)
- Principal Investigator: CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
- Principal Investigator: Remibrutinib in Chronic Spontaneous Urticaria: Early Real-World Effectiveness and Satisfaction
- Principal Investigator: Phase 3 study of remibrutinib in patients with hidradenitis suppurativa
- Principal Investigator: A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects with Notalgia Paresthetica.
- Principal Investigator: A Randomized, Double-Blind, Multi-Center Comparative Effectiveness Study of Spironolactone Versus Doxycycline Hyclate For The Treatment of Acne in Women
- Co-Investigator: Pathogenic exosomes during herpes zoster mediate increased vascular dementia risk
- Sub-Investigator: A Phase 3, Randomized, Placebo-Controlled Double-Blind Study to Evaluate Efficacy and Safety of Upadactinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
- Sub-Investigator: A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
